Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by Cell Genesys.
Recruitment status was  Active, not recruiting
Information provided by:
Cell Genesys Identifier:
First received: May 2, 2005
Last updated: October 1, 2008
Last verified: October 2008

May 2, 2005
October 1, 2008
April 2005
October 2008   (final data collection date for primary outcome measure)
Maximum-tolerated or maximum feasible dose in single and multidose regimens of CG0070 by intravesical administration [ Time Frame: Study End ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00109655 on Archive Site
Assessment of the amount of CG0070 in the urine and blood over time by PCR [ Time Frame: Study End ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure
The main purpose of this research study is to evaluate the safety and dosing of CG0070.
Cohorts of three to six patients will be assigned to receive intravesical (into the bladder) administration of CG0070 either Weekly or Every 4 Weeks for up to a total of 6 doses.
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Carcinoma, Transitional Cell
  • Bladder Neoplasms
Biological: Oncolytic adenovirus (serotype 5) - CG0070
Intravesical administration of CG0070 (in suspension) directly into the bladder
Experimental: 1
Intervention: Biological: Oncolytic adenovirus (serotype 5) - CG0070
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
September 2010
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • High grade non-muscle invasive bladder cancer (stages Ta, T1 and/or CIS - carcinoma in situ). High grade being defined as G2 or G3 disease.
  • Failure of at least one prior treatment with BCG, defined as evidence of TCC on cystoscopic exam and biopsy or cystoscopic exam and urine cytology at least 6 weeks from last BCG treatment
  • ECOG performance status 0-1
  • Adequate bone marrow, renal, liver and coagulation function

Exclusion Criteria:

  • Pregnant or nursing
  • HIV positive
  • Use of anticoagulants such as coumadin or heparin
  • History of bleeding disorder
  • Active systemic autoimmune disease or chronic immunodeficiency
  • Prior gene therapy
  • Uncontrolled cystitis, bladder pain, bladder spasms, urinary incontinence, or reduced bladder volume
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
Not Provided
Cell Genesys, Inc
Cell Genesys
Not Provided
Not Provided
Cell Genesys
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP